Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has provided written informed consent~2. Is ≥18 years of age for patients enrolled in Europe; or ≥20 years of age for patients enrolled in Japan~3. Has definitive histologically or cytologically confirmed SCLC (limited or extensive disease)~4. Has progressed or had recurrence within 30 days prior to randomization~5. Has at least one measurable lesion, as defined by RECIST criteria version 1.1~6. ECOG performance status of 0, 1, or 2~7. Is able to take medications orally~8. Has adequate organ function (bone marrow, kidney and liver)~9. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.~Exclusion Criteria:~1. Has cerebral metastases (unless metastases have been treated and controlled, metastases have been stable for at least 2-months post-intervention, and patient is not receiving corticosteroid treatment)~2. Certain serious illnesses or medical condition(s)~3. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration~4. Has received TAS-102~5. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies~6. Is a pregnant or lactating female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-102 (Type: EXPERIMENTAL): None
- Investigator Choice of Amrubicin or Topotecan (Type: ACTIVE_COMPARATOR): Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)

Based on this trial design, predict the completion outcome and termination type (if applicable).